Elafibranor Appears Beneficial in the Long Term in PBC Elafibranor leads to rapid, sustained, and reproducible responses in clinically relevant biomarkers of fibrosis and cholestasis in PBC, according to a clinical trial.

Biochemical response rates were sustained through week 182 in patients with #PBC treated with #Elafibranor, and the proportion of patients with normal ALP levels remained consistent.

Read more: https://bit.ly/3K8Dipo

#RareDisease #ClinicalTrial #MedSky

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

drug-drug interactions for #elafibranor #iqirvo @IpsenUS
-non hormonal contraception: barrier contraceptive/IUD
-watch liver function tests if need to give rifampin
give at least 4 hours away from cholestyramine or cholestipol

It's a good day for persons living with #PBC with the approval of #elafibranor #iqirvo 80 mg @PBCers @pbcercarol @UKPBC_Project

#livertwitter

@HepDART dr. Martins @Allergan summarizes ph3 trials planned in progress #obeticholicacid #cenicriviroc #aramchol #resmetirom #elafibranor #belapectin #galectin #hepdart

#elafibranor data reassuring as cardiovascular liability is issue with NASH drug development and drug moving to ph3 at 120 mg dose #Liver15

Dr. Harrison: #Elafibranor at 120 mg dose lowers triglycerides, LDL, apoB & C3, Increases HDL vs placebo across disease spectrum #Liver15

Dr. Ratziu: #elafibranor fails to meet primary endpoint in NASH, better effect on more severe disease w/ 120 mg dose #Liver15 #LiverLeader

@AASLDNews #Genfit to present GOLDEN-505 data for #elafibranor at the presidential plenary of #liver15 www.genfit.com/wp-content/uploads/2015/...